ANI Pharmaceuticals

ANI Pharmaceuticals has transformed into a biopharma company focused on rare diseases; Cortrophin Gel remains the primary growth driver, with expected sales of $520–540 million for 2026. For 2026 the company forecasts total revenue of $1.08–1.14 billion and adjusted EBITDA of $285–300 million, while the generics business is expected to be flat in 2026 after a strong prior year. ANI is investing in expansion into acute gouty arthritis (additional costs around $50 million) and has significantly expanded its commercial team; the balance sheet shows about $360 million in cash, room for acquisitions, and a $100 million share buyback program. » More on de.investing.com

At the Wells Fargo Healthcare Conference, ANI Pharmaceuticals reported record revenue ($266 million) and record EBITDA ($71.6 million) for Q2 2026 and stressed an accelerated focus on rare diseases around Cortrophin and ILUVIEN. Cortrophin remained the main growth segment at $117.1 million, but the full-year guidance for Cortrophin was slightly lowered to $520–540 million. The company reported $360 million in cash at the end of June and net leverage of about 1.0x, plans acquisitions only in the rare-disease area, and has approved a $100 million share buyback program. ANI is significantly expanding its field force (from 120 to 180) and expects rare diseases to account for about 60% of revenue by the end of 2026. » More on de.investing.com

ANI Pharmaceuticals' stock fell to a new 52-week low of $70.03, leaving it down about 27.9% year to date. Eight analysts have cut their earnings estimates, although market capitalization ($1.51 billion) and the P/E ratio (15.55) remain. In the second quarter the company beat expectations on adjusted earnings ($2.21 per share) and revenue ($266 million), but cut its full-year forecast for Cortrophin by $20–25 million due to weaker performance in the first half of the year. Analysts reacted mixed: Guggenheim reiterated 'Buy' with a reduced price target, Canaccord kept 'Hold', indicating an overall uncertain outlook. » More on de.investing.com

A Delaware court denied ANI Pharmaceuticals’ requests for a new trial and a modified judgment in a dispute with CG Oncology. ANI plans to appeal to the Delaware Supreme Court and seeks repayment of the value of assets sold in 2010 as well as an ongoing 5% royalty on future worldwide sales of cretostimogene grenadenorepvec. The company did not disclose the scope of the assets claimed or the timetable for the appeal. » More on de.investing.com

ANI Pharmaceuticals reported Q1 2026 EPS of $2.05 (expectation $1.45) and revenue of $237.5M (expectation $213.42M), a 20% increase year-over-year. Growth was driven mainly by products such as Cortrophin Gel (+42% YoY); adjusted non-GAAP EBITDA rose to $63M. The company raised its full-year guidance while the non-GAAP gross margin fell to 60.8%. The stock rose about 4.8% in pre-market trading. » More on de.investing.com